Physician profile
Roberto R Roberti
NPI 1104811561
$2,441.02
in general payments reported to CMS, 2019-2025
30 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $358 · 2021: $451 · 2022: $277 · 2023: $298 · 2024: $160 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $518.78 | 2019-2025 | Repatha, Repatha |
| Astellas Pharma US INC | $249.95 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $217.01 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $196.01 | 2019-2021 | |
| Esperion Therapeutics, INC. | $159.15 | 2021 | |
| Pfizer INC. | $131.41 | 2019-2025 | |
| Novo Nordisk INC | $107.11 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.24 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $84.64 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.19 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $67.19 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $50.82 | 2019-2024 | Watchman Flx |
| Abbott Laboratories | $49.90 | 2022-2025 | Cardiomems |
| Merck Sharp & Dohme LLC | $46.05 | 2022-2025 | Verquvo |
| Medtronic Vascular, INC. | $44.79 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $43.17 | 2019-2023 | |
| Lundbeck LLC | $41.03 | 2020-2021 | |
| Amarin Pharma, INC. | $40.65 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $31.83 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $27.63 | 2019 | |
| Althera Pharmaceuticals LLC | $26.60 | 2021 | |
| Atricure, INC. | $23.64 | 2025 | Atriclip Laa Exclusion System |
| Baxter Healthcare | $18.68 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $17.00 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.00 | 2024 | Edarbyclor |
| Amryt Pharma Holdings LTD | $15.66 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.19 | 2019 | |
| Cvrx, INC. | $9.70 | 2024 | Barostim Neo System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Roberti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.